Clinical trial
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
NCT00334282 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00334282 |
|---|---|
| Title | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma |
| Official title | A Randomised, Double-blind, Placebo Controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/or Metastatic Renal Cell Carcinoma |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Pazopanib, placebo |
| Enrollment | 435 |
| Start date | Apr 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | Dec 1, 2014 |
| First posted | Jun 7, 2006 |
| Last update posted | Feb 5, 2016 |
| Countries | Argentina, Australia, Austria, Brazil, Chile, China, Czechia, Estonia, Greece, Hong Kong, India, Ireland and 13 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: